IGT-427 is a bispecific antibody that potently blocks VEGF and activates Tie-2. Variants of IGT-427 had long intravitreal half-lives, suggesting the potential for a less frequently administered and highly efficacious treatment for diabetic macular edema and wet age-related macular degeneration.
